XTNT Stock Forecast & Price Target

Xtant Medical Holdings is poised for success with its recent acquisition of HEMOBLAST US distribution rights and a strong capital position from the sale of its hardware business. With its focused growth strategy and strong presence in the spine and orthobiologics market, there is potential for Xtant to become a leading player in the global orthobiologics industry. However, competition and potential risks related to ongoing procedures and the need for additional capital should be considered when evaluating the stock. Overall, the stock presents a favorable outlook with limited downside due to its attractive valuation and potential for top-line revenue growth.

Xtant Medical Holdings is facing major headwinds in its spinal implants segment as they face declining revenues and decreased demand for hardware products. In addition, their increased focus on orthobiologics may not be enough to offset these challenges, as evidenced by their lowered guidance for FY26. While the company's cash position and recent asset sale may provide some short-term stability, there are concerns about their long-term sustainability as they navigate through a changing business mix and increased operating expenses.